Saffron and Chamomile
PreclinicalSmall molecule
Saffron and Chamomile is one of 35 small molecule programs targeting Parkinson's Disease. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
53 competitors in Parkinson's Disease
#DrugCompanyPhaseTrials
1Bendopa
MMerz North America, Inc.
Approved
Dayvigo
EisaiApproved
Ingrezza
Neurocrine BiosciencesApproved
Hytrin
AAbbott
Phase 3
Strattera
MMap77
Phase 3
Glucophage
EMD SeronoPhase 3
Micardis
Boehringer IngelheimPhase 3
Plaquenil
Jazz PharmaceuticalsPhase 2
Ketalar
AAultman Health Foundation
Phase 2
Coreg
Akero TherapeuticsPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Saffron and Chamomile. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details